Plain-English translation of NCT07259070 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This early-stage trial is testing a new immunotherapy called , which uses your own immune cells that have been specially engineered in the lab to recognize and attack cancer cells. The treatment is designed for people with certain types of B-cell lymphomas (including DLBCL, CLL, follicular lymphoma, and others) that have returned or no longer respond to standard treatments. Researchers want to find the safest and most effective dose of this medication and learn how well it works.
Many people with B-cell lymphomas eventually stop responding to current treatments, leaving them with limited options. This medication represents a new approach—training immune cells to find and destroy cancer more effectively—which may help patients who have run out of other choices.
You likely qualify if…
You likely don't qualify if…
You will undergo a screening visit to confirm you are eligible, followed by a procedure to collect some of your own immune cells. Your cells will be sent to the lab to be engineered, and meanwhile you may receive chemotherapy to prepare your body. Once the cells are ready, you will receive an infusion of the treatment. You'll then be closely monitored with hospital visits and blood tests to watch for side effects and to see how well the treatment is working. The entire process typically takes several weeks, and you will be followed for at least 12 weeks after the infusion.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China